Bosulif (bosutinib)

Bosutinib (trade name Bosulif) received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy... Wikipedia

 

 

Manufacturer's Website: Bosulif

 

 

Average retail cost: $5,188/month

Search Terms: Bosulif, bosutinib, Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML)